Neoadjuvant chemotherapy in marginally r
✍
Dr. Arthur Skarin; Maxine Jochelson; Thomas Sheldon; Arnold Malcolm; Peter Oliyn
📂
Article
📅
1989
🏛
John Wiley and Sons
🌐
English
⚖ 822 KB
Forty-one patients with marginally resectable stage 111 Mo non-small cell lung cancer (NSCLC) were entered into a study evaluating neoadjuvant cyclophosphamide, adriamycin, and cisplatin chemotherapy (CAP) followed by radiotherapy and subsequent resection. Postoperative radiotherapy and additional C